Apr 13, 2017 - The index experienced an eventful and holiday shortened week, marked by growing geopolitical tensions.
Apr 13, 2017 - NewLink Genetics and Incyte Corporation's IDO-inhibitors could be the next big advance in cancer treatment.
Apr 13, 2017 - Key highlights this week include a complete response letter (CRL) for Merck (MRK) and some positive data from Roche.
Apr 12, 2017 - Bristol-Myers Squibb Company (BMY) announced a collaboration agreement with clinical-stage biopharmaceutical company Apexigen, Inc.
Apr 12, 2017 - Prescription-drug supply shortages have hurt U.S. medical care in recent years. According to new research, they’ve also caused another side effect—drug-price increases.
Apr 12, 2017 - Inovio Pharmaceuticals, Inc. (INO) recently reported positive preliminary results from the expanded stage of its phase I study, EBOV-001.
Apr 10, 2017 - Merck announced that the FDA has denied approval to include cardiovascular outcomes data on the labels of its diabetes drug, Januvia (sitagliptin) and other medicines containing Januvia.
Apr 03, 2017 - Kite Pharma, Inc. (KITE) announced that it has completed the filing of a rolling submission of the Biologics License Application (BLA) for its lead pipeline candidate, axicabtagene ciloleucel to the FDA.
Mar 28, 2017 - Bristol-Myers Squibb Company (BMY) announced that the CHMP has recommended the approval of immunotherapy Opdivo as monotherapy for the treatment of squamous cell cancer of the head and neck (SCCHN) in adults.
Mar 27, 2017 - Merck & Co., Inc. (MRK) recently announced that its anti-PD-1 therapy, Keytruda, has received positive opinion from CHMP for the treatment of patients with relapsed or refractory classical hodgkin lymphoma (cHL).